Comparable stake leader
GENERAL ATLANTIC, L.P.
SEC ownership of Akero Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001744659.
Disclosed value leader
GENERAL ATLANTIC, L.P.
Comparable rows
3/5
Latest evidence
31 Dec 2025
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
GENERAL ATLANTIC, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
3 of 5
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
GENERAL ATLANTIC, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Dec 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001744659
- Issuer location
- South San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Akero Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GENERAL ATLANTIC, L.P.
Disclosed value leader
GENERAL ATLANTIC, L.P.
Comparable rows
3/5
Latest evidence
31 Dec 2025
13D/G
3/4/5
Lead comparable stake: 8.4%
2 rows are not safely comparable across share classes.
13D/G row: GENERAL ATLANTIC, L.P.
Quick read
GENERAL ATLANTIC, L.P. leads the comparable SEC ownership view at 8.4%.
3 of 5 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GENERAL ATLANTIC, L.P.'s linked filing trail.
Comparable ownership
Top 3
GENERAL ATLANTIC, L.P.
8.4%
PRICE T ROWE ASSOCIATES INC /MD/
4.8%
Janus Henderson Group Ltd.
4.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-5 of 5 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GENERAL ATLANTIC, L.P. |
13D/G
|
8.4%
|
$278,656,049
6,796,489 shares
|
$0 | 31 Mar 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13D/G
T. Rowe Price Associates, Inc.
|
4.8%
|
$180,902,408
3,810,076 shares
|
$0 | 30 Sep 2025 |
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
4.1%
|
$138,062,973
3,397,779 shares
|
-$117,126,544 | 31 Dec 2025 |
| Skorpios Trust |
3/4/5
Former 10% owner
|
—
class O/S missing
|
$2,012,175
3,271,829 shares
|
— | 01 Dec 2022 |
| Kevin Bitterman |
3/4/5
Director
|
—
class O/S missing
|
—
13,000 shares
|
— | 01 Jun 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$4,824,822.
Buys
$0
Insiders: 0
Sells
$4,824,822
Insiders: 5
Net
-$4,824,822
Shares: -101,753
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 101,753
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 101,753 | $0 | $4,824,822 | -$4,824,822 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to Akero Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
Skorpios Trust
Net 12M change
-$4,824,821
Latest report
09 Dec 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Skorpios Trust | Former 10% owner | $2,012,175 | Mixed | 01 Dec 2022 | ||
| Andrew Cheng | President and CEO, Director | $0 | -$2,994,005 | -100% | Mixed | 09 Dec 2025 |
| G. Walmsley Graham | Director | $0 | Mixed | 09 Dec 2025 | ||
| Jonathan Young | Chief Operating Officer | $0 | -$622,188 | -100% | Mixed | 09 Dec 2025 |
| Catriona Yale | Chief Development Officer | $0 | -$28,350 | -100% | Mixed | 09 Dec 2025 |
| Patrick Lamy | Senior VP, Commercial Strategy | $0 | Mixed | 09 Dec 2025 | ||
| Chou Judy | Director | $0 | Mixed | 09 Dec 2025 | ||
| Scott A. Gangloff | Chief Technology Officer | $0 | Mixed | 09 Dec 2025 | ||
| Iwicki Mark T. | Director | $0 | Mixed | 09 Dec 2025 | ||
| Yuan Xu | Director | $0 | Mixed | 09 Dec 2025 | ||
| Tomas J. Heyman | Director | $0 | Mixed | 09 Dec 2025 | ||
| William Richard White | Chief Financial Officer | $0 | -$28,350 | -100% | Mixed | 09 Dec 2025 |
| Seth Loring Harrison | Director | $0 | Mixed | 09 Dec 2025 | ||
| Timothy Rolph | Chief Scientific Officer | $0 | -$1,151,928 | -100% | Mixed | 09 Dec 2025 |
| Jane Pritchett Henderson | Director | $0 | Mixed | 09 Dec 2025 | ||
| Kevin Bitterman | Director | Mixed | 01 Jun 2021 | |||
| ATP Life Science Ventures, L.P. | 10%+ Owner | Mixed | 28 Jun 2021 |
Recent insider transactions for Akero Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Tomas J. Heyman | AKRO | Common Stock | Disposed to Issuer | -100% | -9,398 | 0 | 09 Dec 2025 | Direct | ||
| Tomas J. Heyman | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -69,000 | 0 | 09 Dec 2025 | Direct | ||
| Yuan Xu | AKRO | Common Stock | Disposed to Issuer | -100% | -9,398 | 0 | 09 Dec 2025 | Direct | ||
| Yuan Xu | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -95,000 | 0 | 09 Dec 2025 | Direct | ||
| Andrew Cheng | AKRO | Common Stock | Disposed to Issuer | -100% | -436,837 | 0 | 09 Dec 2025 | Direct | ||
| Andrew Cheng | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -1,678,754 | 0 | 09 Dec 2025 | Direct | ||
| Seth Loring Harrison | AKRO | Common Stock | Disposed to Issuer | -100% | -148,063 | 0 | 09 Dec 2025 | See Footnote | ||
| Seth Loring Harrison | AKRO | Common Stock | Disposed to Issuer | -100% | -145,699 | 0 | 09 Dec 2025 | Direct | ||
| Seth Loring Harrison | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -108,000 | 0 | 09 Dec 2025 | Direct | ||
| G. Walmsley Graham | AKRO | Common Stock | Disposed to Issuer | -100% | -1,200,000 | 0 | 09 Dec 2025 | See Footnote | ||
| G. Walmsley Graham | AKRO | Common Stock | Disposed to Issuer | -100% | -102,398 | 0 | 09 Dec 2025 | Direct | ||
| G. Walmsley Graham | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -15,000 | 0 | 09 Dec 2025 | Direct | ||
| Chou Judy | AKRO | Common Stock | Disposed to Issuer | -100% | -9,398 | 0 | 09 Dec 2025 | Direct | ||
| Chou Judy | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -82,000 | 0 | 09 Dec 2025 | Direct | ||
| Timothy Rolph | AKRO | Common Stock | Disposed to Issuer | -100% | -282,149 | 0 | 09 Dec 2025 | Direct | ||
| Timothy Rolph | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -406,014 | 0 | 09 Dec 2025 | Direct | ||
| Iwicki Mark T. | AKRO | Common Stock | Disposed to Issuer | -100% | -9,398 | 0 | 09 Dec 2025 | Direct | ||
| Iwicki Mark T. | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -240,307 | 0 | 09 Dec 2025 | Direct | ||
| Scott A. Gangloff | AKRO | Common Stock | Disposed to Issuer | -100% | -26,351 | 0 | 09 Dec 2025 | Direct | ||
| Scott A. Gangloff | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -296,100 | 0 | 09 Dec 2025 | Direct | ||
| William Richard White | AKRO | Common Stock | Disposed to Issuer | -100% | -57,752 | 0 | 09 Dec 2025 | Direct | ||
| William Richard White | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -661,075 | 0 | 09 Dec 2025 | Direct | ||
| Catriona Yale | AKRO | Common Stock | Disposed to Issuer | -100% | -74,800 | 0 | 09 Dec 2025 | Direct | ||
| Catriona Yale | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -456,575 | 0 | 09 Dec 2025 | Direct | ||
| Patrick Lamy | AKRO | Common Stock | Disposed to Issuer | -100% | -29,891 | 0 | 09 Dec 2025 | Direct | ||
| Patrick Lamy | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -212,664 | 0 | 09 Dec 2025 | Direct | ||
| Jane Henderson | AKRO | Common Stock | Disposed to Issuer | -100% | -9,398 | 0 | 09 Dec 2025 | Direct | ||
| Jane Henderson | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -93,797 | 0 | 09 Dec 2025 | Direct | ||
| Jonathan Young | AKRO | Common Stock | Disposed to Issuer | -100% | -20,000 | 0 | 09 Dec 2025 | By JL Irrevocable Trust | ||
| Jonathan Young | AKRO | Common Stock | Disposed to Issuer | -100% | -20,000 | 0 | 09 Dec 2025 | By CM Irrevocable Trust | ||
| Jonathan Young | AKRO | Common Stock | Disposed to Issuer | -100% | -20,000 | 0 | 09 Dec 2025 | By EA Irrevocable Trust | ||
| Jonathan Young | AKRO | Common Stock | Disposed to Issuer | -100% | -200,189 | 0 | 09 Dec 2025 | Direct | ||
| Jonathan Young | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -512,082 | 0 | 09 Dec 2025 | Direct | ||
| Jonathan Young | AKRO | Common Stock | Gift | -4.42% | -9,259 | 200,189 | 26 Nov 2025 | Direct | ||
| Timothy Rolph | AKRO | Common Stock | Options Exercise | 117.9% | 152,678 | 282,149 | 25 Nov 2025 | Direct | ||
| Timothy Rolph | AKRO | Stock Option (Right to Buy) | Options Exercise | -100% | -152,678 | 0 | 25 Nov 2025 | Direct | ||
| Jonathan Young | AKRO | Common Stock | Options Exercise | 6.37% | 12,550 | 209,448 | 24 Nov 2025 | Direct | ||
| Jonathan Young | AKRO | Stock Option (Right to Buy) | Options Exercise | -100% | -12,550 | 0 | 24 Nov 2025 | Direct | ||
| Andrew Cheng | AKRO | Common Stock | Gift | -14.6% | -74,538 | 436,837 | 20 Nov 2025 | Direct | ||
| Timothy Rolph | AKRO | Common Stock | Gift | -22.3% | -37,100 | 129,471 | 17 Nov 2025 | Direct | ||
| Andrew Cheng | AKRO | Common Stock | Gift | -2.8% | -14,739 | 511,375 | 12 Nov 2025 | Direct | ||
| Catriona Yale | AKRO | Common Stock | Options Exercise | 12.4% | 8,266 | 74,800 | 04 Nov 2025 | Direct | ||
| Catriona Yale | AKRO | Stock Option (Right to Buy) | Options Exercise | -100% | -8,266 | 0 | 04 Nov 2025 | Direct | ||
| Andrew Cheng | AKRO | Common Stock | Sale | -5.39% | $1,619,340 | $53.98 | -30,000 | 526,114 | 10 Oct 2025 | Direct |
| Andrew Cheng | AKRO | Common Stock | Options Exercise | 5.7% | 30,000 | 556,114 | 10 Oct 2025 | Direct | ||
| Andrew Cheng | AKRO | Stock Option (Right to Buy) | Options Exercise | -7.32% | -30,000 | 380,017 | 10 Oct 2025 | Direct | ||
| G. Walmsley Graham | AKRO | Common Stock | Options Exercise | 4189.7% | 90,832 | 93,000 | 08 Oct 2025 | Direct | ||
| G. Walmsley Graham | AKRO | Stock Option (Right to Buy) | Options Exercise | -100% | -90,832 | 0 | 08 Oct 2025 | Direct | ||
| Andrew Cheng | AKRO | Common Stock | Options Exercise | 11% | 52,212 | 526,114 | 08 Oct 2025 | Direct | ||
| Andrew Cheng | AKRO | Stock Option (Right to Buy) | Options Exercise | -100% | -52,212 | 0 | 08 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.